Catch Up on LRA News with Lupus Research Update Vol. 1, 2022
En Español
Email Sign Up
Give
Search
En Español
Sign Up for Updates
Who We Are
About Us
Our Impact
Strategic Plan Highlights
Our History
Our Commitment to DE&I
Financials
Careers
Leadership and Partners
Board of Directors
Research Committee of the Board
Scientific Advisory Board
Leadership and Partners
Executive Staff
Young Leaders Board
Complexity of Lupus
Why Is Lupus So Complex?
About Lupus
Symptoms
How is Lupus Diagnosed?
Treatment
Educational Resources
Our Research
About Our Research
Research Roadmap
Research We Fund
Get Involved in Research
Lupus Nexus
Participate in the Lupus Landmark Study
Lupus Therapeutics, LLC
For Researchers
Funding Opportunities
Funded Research
Research Partners
Scientific Resources
Research Contacts
LRA Reviewers 2022 – 2023
Press
Stories & News
Get Involved
Give
Online Donation
Other Ways to Give
Sponsorship Opportunities
Research
Find a Clinical Trial
Give to the Lupus Brain Bank
Participate in the Lupus Landmark Study
Events
Join Our Events
Walk
Host an Event
Volunteer
Educate Your Community
Advocate
Advocate
Results
Advocacy News
Contact
Stories & News
News Update
Catch Up on LRA News with Lupus Research Update Vol. 1, 2022
February 17, 2022 It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year in...
News Update
Lupus Research Alliance Congratulates Dr. Robert Califf on FDA Commissioner Appointment
February 17, 2022 The Lupus Research Alliance applauds the appointment of Dr. Robert Califf as the Commissioner of the U.S. Food...
News Update
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results...
Story
LRA-Funded Research Aims at Preventing Heart Disease in Kids With Lupus
February 14, 2022 Being a kid isn't always easy, but growing up with lupus makes it a much harder challenge. That’s...
News Update
LRA-Funded Research Found a Connection Between the Epstein-Barr Virus Infection and MS as an Autoimmune Disease
February 4, 2022 A potential new cause of the autoimmune disease multiple sclerosis (MS) was discovered by researchers partly funded by...
News Update
Baricitinib Development as a Lupus Treatment Discontinued
January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a potential...
News Update
LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis
January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration...
News Update
Shingles Vaccine Recommended for Immunocompromised People
January, 2022 As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the vaccine...
News Update
FDA Authorizes Evusheld Emergency Use to Prevent COVID-19 in Immunocompromised Patients
December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune system...
News Update
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals...
News Update
LRA Partnering with NIH, FNIH and Others on Groundbreaking Initiative
December 9, 2021 The Lupus Research Alliance (LRA) is proud and excited to partner again with the National Institutes of Health...
Story
Thanks To NY JETS for Hosting LUPUS AWARENESS DAY November 21
November 22, 2021 The New York Jets and Lupus Research Alliance (LRA) hosted Lupus Awareness Day on November 21, 2021, at...
Posts pagination
◀︎
1
…
8
9
10
11
12
…
51
▶︎
Search Our Site
Search
X